

Advinus meets milestone in drug discovery alliance

07 November 2014 | News | By BioSpectrum Bureau

Advinus meets milestone in drug discovery alliance



The achievement of this milestone substantiates the successful path of the collaboration and confirms Advinus' proven strength in providing innovative solutions with speed and quality - essential ingredients for discovery of safe and effective medicines.

A payment of \$3 million has been made by Takeda to Advinus to mark the achievement.

In October 2012, Advinus and Takeda announced a multi-year multi-project collaboration in the area of drug discovery.

In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.

In October 2013, Advinus met the milestone that was set to mark the end of the first year of the collaboration.

The rapid progress of the research programs over the past year has resulted in the milestone to mark the completion of the second year of the collaboration.

"The rapid progression of the collaborative programs by Advinus' young and talented scientists has strengthened the Takeda-Advinus partnership, and the approval of the milestone demonstrates the confidence that Takeda has in Advinus' ability to

deliver novel and effective candidates for drug development in a rapid and cost effective manner," said Dr Kasim Mookhtiar, CSO, Advinus.